FDAnews Device Daily Bulletin

EnteroMedics’ Obesity Study Yields Positive Results

April 7, 2016

EnteroMedics says positive results from its ReCharge study evaluating its vBloc neurometabolic therapy in moderately obese patients with a related comorbid condition have been published in the journal Obesity Surgery.

Patients with vBloc experienced 74 percent greater weight loss compared with a control, with an average loss of 33 percent excess weight at 12 months. Additionally, a third of the patient pool lost at least 20 percent, and a quarter lost at least 50 percent.

No serious adverse events occurred through 12 months, according to the company. — Anisa Jibrell